Compare HP Inc (HPQ) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HP Inc vs Inovio Pharmaceuticals Inc — how do they compare? HP Inc trades at $25.09 (market cap $22.69B), while Inovio Pharmaceuticals Inc trades at $1.08 (market cap $90.50M). The key difference: HP Inc is far larger — about 250.7× Inovio Pharmaceuticals Inc's market cap, and HP Inc pays a 4.84% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| HPQ | INO | |
|---|---|---|
Market Cap | $22.69B | $90.50M |
Sector | Technology | Health |
52-Week High | $29.35 | $2.87 |
52-Week Low | $18.20 | $1.05 |
Enterprise Value | $29.85B | $61.51M |
Dividend Yield | 4.84% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HPQ trades at $24.81, down 0.12% on the day, with a bullish technical signal from moving averages and a neutral RSI. The stock shows attractive valuation with a P/E of 8.97 and P/S of 0.4, supported by consistent earnings beats in recent quarters. Recent news highlights AI-driven upgrade cycles and strategic partnerships, including with OpenAI, positioning HP for growth in the AI PC market. Cash flow trends have improved, with net cash flow turning positive in 2025.
The outlook for HPQ is cautiously optimistic, driven by potential AI PC adoption and solid fundamentals, but risks include competitive pressures and cyclical demand. Analyst consensus is mixed with a hold rating, and the current price is above the consensus target of $22.00, suggesting limited near-term upside. Investors should weigh the dividend yield and valuation against market volatility and execution risks.
INO trades at $1.10, down 1.79% recently, with a bearish technical signal from moving averages. The company shows minimal revenue of $65,340 in 2025 and a net loss of $84.95 million, resulting in negative profitability margins. Recent news highlights an ongoing FDA review for INO-3107 with a PDUFA date of October 30, 2026, while shareholder litigation investigations emerge. Cash flow remains negative, though operating expenses have declined.
The investment case hinges on the binary FDA decision for INO-3107, offering potential upside if approved, but carries high risk due to persistent losses, negative cash flow, and legal scrutiny. Analyst consensus is moderately bullish with 53% buy ratings, but fundamental weaknesses and technical bearishness suggest cautious positioning is warranted.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About HP Inc
HP Incorporated is a leading provider of computers, printers, and printer supplies. The company's mains segments are personal systems and printing. Its personal systems segment contains notebooks, desktops, and workstations. Its printing segment contains supplies, consumer hardware, and commercial hardware. In 2015, Hewlett-Packard was separated into HP Incorporated and Hewlett Packard Enterprise and the Palo Alto, California-based HP Incorporated sells on a global scale.
Read more on HPQ →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
